Introduction
============

In modern society, chemicals are indispensable for everyday human life. Numerous chemicals are used to maintain and improve the quality of life, including cosmetics, toiletries, detergents, air fresheners, agrochemicals such as pesticides and fertilizers, disinfectants, sterilizers, preservatives and industrial solvents. Chemicals are also employed in the manufacture of various product-comprising ingredients or parts like coatings/paints, photo-resistant treatments, batteries, automobiles, packaging and many more uncountable uses. One recent report estimated that as many as 80000 to 120000 chemicals are currently in use worldwide, with an additional 2000 chemicals newly introduced each year \[[@b1-eht-31-e2016026],[@b2-eht-31-e2016026]\]. In Korea, approximately 44000 chemicals are known to be in use and about 300 new chemicals are newly marketed annually \[[@b3-eht-31-e2016026]\]. Accordingly, exposure to humans and the environment is unavoidable, which can be accompanied by adverse effects to human health and/or the environment.

The potential danger of chemical exposure and its devastating outcomes has been strikingly exemplified by the recent tragic accident surrounding oligo(2-(2-ethoxy)ethoxyethyl guanidine chloride/polyhexamethyleneguanidine, which were inadvertently used to sterilize humidifiers \[[@b4-eht-31-e2016026]\]. These chemicals, which were originally developed as carpet sterilizers, when used in humidifiers, resulted in high doses via inhalational exposure and unanticipated lung fibrosis, which cost 701 innocent lives, mostly newborn babies and nursing mothers \[[@b5-eht-31-e2016026]\]. To better protect humans and the environment against exposure to toxic chemicals, the Act on the Registration and Evaluation of Chemicals (K-REACH), was enacted and has been in force since 2015, mandating the registration of a chemical before its release onto the market with relevant information on human health and environmental hazards \[[@b6-eht-31-e2016026]\].

Act on the Registration and Evaluation of Chemicals: Data Requirements, Test Guidelines and Skyrocketing Animal Use
===================================================================================================================

K-REACH is the Korean version of the European Registration, Evaluation, Authorization and Restriction of Chemicals (EU-REACH) regulation. K-REACH originally aimed to manage the risk stemming from chemical exposure by providing relevant information on intrinsic hazards and guidance regarding safe use, such as by providing proper classification and labeling \[[@b7-eht-31-e2016026]\]. In this respect, it is aligned with the United Nation (UN) Globally Harmonized System of Classification and Labeling of Chemicals (GHS) \[[@b8-eht-31-e2016026]\]. The UN GHS hazard class system categorizes chemicals according to its level of health hazard as an axis and toxic outcomes or endpoints as another. Accordingly, the effects of chemicals on the respective toxic endpoints is evaluated to obtain safety data so the chemical can be properly classified. Depending on the volume or tonnage of the chemical used, the level and range of information required varies, as shown in [Table 1](#t1-eht-31-e2016026){ref-type="table"}. Notably, K-REACH does not incorporate many of the animal welfare provisions contained in its European counterpart regulation, e.g., the Article 1 requirement to promote alternatives to animal testing, the Article 13 requirement to generate new data wherever possible by means other than vertebrate animal tests, the Article 25 requirement to avoid unnecessary testing, and the Annex XI rules for waiving or otherwise adapting standard data requirements \[[@b9-eht-31-e2016026]\]. According to the list of tests required by K-REACH shown in [Table 1](#t1-eht-31-e2016026){ref-type="table"}, for chemical substances manufactured or imported in volumes of 1000 tons or more per year, the data package must include 46 test items; this entails a huge amount of money and resources. Furthermore, to generate health hazard and ecotoxicology packages using conventional test guideline methods, the animal use would be astronomical. In the worst case scenario, the number of animals required per substance would be nearly 6000, just for the assessment of human health effects, at a cost of more than 1.5 billion Korean won. The number of animals required and the costs for each test are listed in [Table 2](#t2-eht-31-e2016026){ref-type="table"}.

Given that about 300 chemicals are newly introduced into Korean market every year, the use of animals would be enormous without any drastic changes. Statistics published recently by the Korean Ministry of Agriculture, Food and Rural Affairs (MAFRA) reflects a 36.7% increase in experimental animal use between 2012 and 2015 (2012, 1834000; 2013, 1967000; 2014, 2412000; 2015, 2507000) \[[@b10-eht-31-e2016026]\]. This problem is not unique to Korea. Following the enactment of REACH in the EU, the European Chemicals Agency has estimated that 30000 substances will be registered, requiring upwards of 3.9 million animals to be used in tests costing €1.6 billion (US\$ 2.3 billion) \[[@b11-eht-31-e2016026],[@b12-eht-31-e2016026]\]. However, others have suggested that the European Chemicals Agency's estimates may represent a substantial underestimation of both chemical registrations and animal use, projecting on the order of 68000 substance registrations and use of 54 million animals, respectively \[[@b13-eht-31-e2016026]\]. Thus, the European public has demanded swift action by authorities and industry to ensure effective sharing of existing data, uptake of validated alternatives to animal tests, and other scientifically supported replacement, reduction or refinement (3R) best practices.

Limitation and Problems of Conventional Animal Experiments
==========================================================

Conventional animal experiments have been developed and used on the premise that the responses of animals in the laboratory to chemicals can provide information to predict those of humans in the real world. However, this basis is somewhat incorrect with respect to species differences in genetic expression, absorption, distribution, metabolism and excretion, organ susceptibility, immune responses and resistance or tolerance to xenobiotics. This point has been explicitly criticized by Leist and Hartung \[[@b14-eht-31-e2016026]\], who stated that "the human is not a 70 kg rat." Indeed, rats, one of the most widely exploited experimental animal species, have different metabolic capacity and immune responses to humans, which seriously undermines the predictability of the experimental data \[[@b15-eht-31-e2016026]\]. Another important point which diminishes the utility of animal experiments is that extreme conditions are generally employed as the "worst case scenario" in view of chemical exposure levels (extremely high doses ranging from 10-fold to 1000-fold higher than human exposure levels) \[[@b16-eht-31-e2016026]\], exposure route (forced eyelid eversion for ocular irritant administration and closure for persistent exposure, or injection into sutured oral pouches to simulate oral mucosal exposure), stress (unrealistically stressful conditions like cold or hot conditions), or disease states (no animal naturally exhibits an asthmalike syndrome that is similar to the disease in humans) \[[@b17-eht-31-e2016026]\].

Although these experimental approaches may save time (using a high dose to curtail the time factor) and cost, they frequently produce unrealistic and inaccurate dose-response data for the prediction of human responses. Exemplifying this, endocrine disrupting chemicals generally exhibit unconventional non-linear, bell-shaped or U-shaped dose-response patterns that cannot be properly evaluated in high-dose animal experiments \[[@b18-eht-31-e2016026]\]. The dose-limiting toxicity of drug candidates observed in animal tests mostly do not appear in human clinical trials and the poor predictability of animal experiments has been observed across diverse target tissues \[[@b19-eht-31-e2016026]\]. Due to the failure of clinical trials by the appearance of unscreened toxicity during preclinical trials, enormous amounts of money and time are wasted \[[@b20-eht-31-e2016026]\]. In this context, the development of more human-relevant and advanced methods is necessary to replace or at least to supplement traditional animal tests.

In addition to the major scientific drawbacks described above, animal tests have been criticized for their inherent cruelty, for being excessively time-intensive and resource-intensive, restrictive in the number of substances or mixtures that can be tested, and of little value in understanding the mechanistic underpinnings of toxicity in the species of ultimate interest.

New Methods as Replacements for Conventional Animal Tests
=========================================================

The last century has witnessed unprecedented scientific and technological advances in biology, represented by human whole genome sequencing \[[@b21-eht-31-e2016026]\], the birth of functional genomics \[[@b22-eht-31-e2016026]\], computational biology, and high-speed robot automation of cell-based (*in vitro*) screening systems \[[@b23-eht-31-e2016026]\]. These innovations are being incorporated into a wide range of health and molecular/cellular biological research sectors, providing renewed vigor and inspiration in these areas. Numerous novel and revolutionary biochemical and molecular tools have been developed through this innovation, including high throughput assays, quantitative real time-polymerase chain reaction, flow cytometry, high content assays, gene transfection, reporter gene assays and tissue engineering. in fact, these new tools have helped to understand how toxicants disrupt the normal physiology of the human body at the cellular and molecular levels, which has contributed to the birth of molecular and mechanistic toxicology \[[@b24-eht-31-e2016026]\]. The resulting predictions regarding human safety and the risk of a chemical are potentially more relevant to people than animal tests. In line with this, the Toxicology for the 21st Century or "Tox21" strategy has been embarked on with a grand vision "to innovate virtually all routine toxicity testing to be conducted in human cells or cell lines" \[[@b25-eht-31-e2016026]\]. These non-animal based new testing methods enable safety evaluations of a much larger number of substances, in a more rapid, efficient and cost-effective way. Most importantly, these methods are likely to be more relevant to toxicity in humans, as well as capable of identifying the cellular mechanisms of toxicity using fewer or no animals \[[@b26-eht-31-e2016026],[@b27-eht-31-e2016026]\].

Development of Non-animal Based Alternatives and Their Adoption by Regulatory Science
=====================================================================================

Safety and regulatory science is one of most conservative and slowest-moving sectors in taking up new and novel methods, since many countries with diverse cultural and socioeconomic backgrounds must comply with new regulation through so-called "international and inter-regional harmonization". Moreover, there are various stakeholders with conflicting interests even within a single country. This is understandable, since important policies like drinking water standards, sewage control, emission limits, inclusion on positive or negative lists, and authorizing the use of chemicals are based upon safety evaluations and risk assessments, which often cost enormous amounts of money to achieve compliance, with serious risks to public health or the environment in the absence of compliance. Prior to implementation, a newly developed method must be compared regarding its relevance and reliability to the original gold standard method or targeted toxicity endpoint in humans in a validation trial, which can take as long as 10 years from the initial research and development steps \[[@b28-eht-31-e2016026]\]. The results of validation studies are then subject to regulatory adoption processes, involving appraisal by experts with multi-disciplinary backgrounds, often with the participation of more than one regulatory body from multiple countries.

International regulatory bodies or collaborative organizations that can represent a large number of countries, like the Organization for Economic Cooperation and Development (OECD), the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use and the International Organization for Standardization have participated in these review and appraisal processes to accommodate the opinions of member countries. Of these, the OECD is the most active in publishing and updating new test guidelines (TGs), along with integrated approaches to testing and assessment and other guidance materials, which 35 member countries can follow as the standardized methods. Many *in vitro* or *in vivo* tests with animal replacement, reduction or refinement potential have been included as TGs recently, as shown in [Table 3](#t3-eht-31-e2016026){ref-type="table"} \[[@b29-eht-31-e2016026]\], indicating 3R concepts applied to TGs, which are classified according to toxic endpoints. While non-animal tests have been actively developed and widely used in skin or eye irritation tests, the alternative tests are not yet established for acute toxicity or reprovductive toxicity.

OECD TGs on toxicity tests were first developed in early 1980s, and have been revised continuously by 3R concepts and with the progression of science. From the 1980s to the early 2000s, mainly *in vivo* methods using animals were adopted as TGs, and the pace of development or the appearance of new methods was slow. However, since the late 2000s, the TGs have been annually revised with 3R concepts, and many new alternative animal tests have been adopted ([Table 3](#t3-eht-31-e2016026){ref-type="table"}), and many old or obsolete TGs can now be abandoned. The number of TG revisions by year is shown in [Figure 1](#f1-eht-31-e2016026){ref-type="fig"} \[[@b27-eht-31-e2016026]\].

Human biology-based *in vitro* methods are typically more relevant and predictive, less time-consuming, can accommodate larger number of chemicals or mixtures than traditional animal experiments, and can address the mechanism of toxicity using the framework of an adverse outcome pathway (AOP). By systemically categorizing the biological events leading to adverse effects into key events between two points, i.e., a molecular initiating event and an adverse outcome, the AOP describes an adverse outcome following exposure to a chemical by a series of key events and key event relationships that describe the causal relationships between the key events. AOPs are instrumental for establishing the toxic mechanism of an adverse outcome and the utilization of safety test data at the *in vitro*, *in vivo* and human levels for risk assessments and regulatory applications. In the best case scenario, the number of animals saved by employing multiple *in vitro* tests along with limited *in vivo* tests will be in the thousands, which will significantly contribute to animal ethics without compromising predictive capacity or risking human health or environmental protection.

Pros and Cons of *In Vitro* Alternatives to Animal Tests
========================================================

Ultimately and ideally, all animal experiments, including those with refined or reduced use of animals, are to be changed into non-animal based methods. These methods can be largely categorized into *in chemico*, *ex vivo* and *in vitro* methods. Approved OECD TGs fall into these categories, as shown in [Table 4](#t4-eht-31-e2016026){ref-type="table"}.

Since these methods largely employ test-tube or multi-well plate formats, the throughput is much higher than traditional animal experiments. For example, the 3D reconstructed human cornea-like epithelium (RhCE) method can evaluate the ocular irritancy of 10 test substances in one run, which takes three days from the delivery of the model \[[@b28-eht-31-e2016026]\]. This test is equivalent to 10 tests using the *in vivo* Draize rabbit eye irritation test, costing the lives 30 of rabbits and taking at least 10 days from the delivery of the rabbits \[[@b30-eht-31-e2016026]\]. This test can be harnessed to assess multiple combinations of test conditions like different mixture ratios, diverse exposure scenarios and the addition of metabolic capacity using a feasible amount of time and money \[[@b27-eht-31-e2016026]\]. Moreover, through targeting a single molecular event on the AOP framework, the conclusions of alternative methods may be more direct and straightforward, which is critical to address the mechanism of toxicity and extrapolation into human responses. For example, in the direct peptide reactivity assay, an *in chemico* skin sensitization test that addresses the haptenization response of a substance, positive results indicate that the chemical is reactive and can form protein adducts \[[@b31-eht-31-e2016026]\].

Of course, there are limitations and shortcomings of non-animal methods as well. First, most of the alternatives have not advanced into the level of risk assessment, since they only give a qualitative "yes" or "no" answer, namely hazard identification. Even though some methods give quantitative data, their utility for potency classification or risk assessment has not been fully validated \[[@b32-eht-31-e2016026]\]. In addition, since the alternatives address mostly a single key event in the series of events constituting a larger AOP, they cannot provide the full mechanistic information regarding the final outcome of the initial exposure \[[@b33-eht-31-e2016026]\]. In this case, a combination of multiple *in vitro* assays can be used as an integrated approach to testing and assessment (IATA) \[[@b34-eht-31-e2016026]\]. Indeed, considerable efforts have been directed toward developing a standardized IATA scheme.

Barriers to Acceptance of Non-animal Based Alternatives in Act on the Registration and Evaluation of Chemicals and Recommendations
==================================================================================================================================

Although many validated and internationally recognized nonanimal methods and strategies are now available and ready for immediate use in regulatory frameworks such as K-REACH, their uptake by Korean authorities continues to be less than optimal. Whereas EU-REACH data requirements and guidance have been or are being amended to incorporate all available OECD 3R TGs and related best practices, such is not yet the case with K-REACH \[[@b35-eht-31-e2016026],[@b36-eht-31-e2016026]\]. This is in part due to the lack of a "mandatory 3R" requirement under K-REACH and other legislation for the uptake of new methods. In addition, there is a lack of inter-ministerial cooperation regarding the uptake of new methods. For example, the Korean Centre for the Validation of Alternative Methods has been established under the Ministry of Food and Drug Safety (MFDS), but does not currently include participation from other regulatory or research agencies in the development, validation or regulatory review of non-animal based methods \[[@b37-eht-31-e2016026]\], indicating the inter-ministerial inefficiency and passive attitudes towards new and more advanced methods. Delayed implementation of 3R-based alternatives, due to these inefficiencies, would lead to the unnecessary sacrifice of laboratory animals, even though they are not better than new alternatives for the protection of human health and the environment.

There are also duplicate experiments for substances that have already been tested and assigned GHS classifications, including chemicals that are known corrosives, fatal if inhaled or probable carcinogens. The scientific basis for duplicating well-established test results and regulatory classifications is incomprehensible, particularly where vertebrate animal testing would be involved, and most notably where such testing (e.g., of corrosives) would result in the most extreme pain and suffering for the animals involved.

To ensure that the Korean regulatory framework for chemicals, and the general approach to the validation and adoption of 3R best practices, do not fall farther behind those of other developed nations, K-REACH data requirements and TGs must be immediately and frequently amended on regular basis to incorporate all relevant OECD 3R TGs and related best practices, including mandatory data sharing, chemical grouping and readacross to ensure maximum possible reduction of vertebrate animal use and no duplication of existing test results. One overarching regulatory body shall be formed to include all Korean ministries with a stake in alternative methods and safety assessment, including the MFDS, the Ministry of Environment (MOE), and the MAFRA to facilitate inter-ministerial cooperation toward the development of a comprehensive government strategy and funding framework for the reduction and replacement of animals used for toxicity testing and life sciences research \[[@b38-eht-31-e2016026]\].

Conclusion
==========

The implementation of K-REACH will contribute to the safe use of chemicals by identifying human health effects and ecotoxicity before their introduction to human society and the environment. However, a huge number of laboratory animals are required to comply with the current Korean guidelines, which is sometimes unnecessary and can be replaced with alternative methods. Therefore, in order for K-REACH to be more practically implemented, 3R concepts and alternative to animal tests (AATs) should be actively accepted, which has been advanced in the developed countries. Using AATs for safety assessment is scientific, highly reliable and predictable and may be more human-relevant without inflicting pain and death in laboratory animals. Moreover, the application of AATs may be more economical and effective than animal tests. The implementation of AATs is also a concern in other chemical sectors such as the food, cosmetics, drug and agrochemical industries. In this regard, the collaboration of the MOE, the MFDS, and MAFRA in Korea is critical. Korean regulatory authorities should actively communicate and collaborate to follow global trends in safety assessments and rapidly developing alternative tests.
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###### 

Requirement of data for Act on the Registration and Evaluation of Chemicals registration

  Field                       Tonnage \[no. of test\]^[a](#tfn1-eht-31-e2016026){ref-type="table-fn"}^                                                                                                                            
  --------------------------- -------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Physicochemical property    State of substance                                                         Flammability                                         Viscosity                                                           
                              Water sdubility                                                            Explosiveness                                        Dissociation constant                                               
                              Melting/freezing point                                                     Oxidation                                                                                                                
                              Boiling point                                                                                                                                                                                       
                              Vapor pressure                                                                                                                                                                                      
                              Octanol/water partitioning coefficient                                                                                                                                                              
                              Density                                                                                                                                                                                             
                              Particle size analysis                                                                                                                                                                              
  Hazard on human health      Acute toxicity-oral (acute toxicity-inhalation)                            Acute toxicity-dermal route or inhalation            Additional genotoxicity test (reproductive cell and genotoxicity)   Repeated dose toxicity study (90 d)
                                                                                                                                                                                                                                  Teratogenicity
                              Ames test (bacterial reverse mutation assay)                               Eye irritation/corrosion                                                                                                 Two-generation reproductive toxicity
                                                                                                         Chromosomal aberration test                                                                                              Carcinogenicity
                              Skin irritation/corrosion                                                  Genotoxicity test                                                                                                        
                              Skin sensitization                                                         Repeated dose toxicity study (28 d)                                                                                      
                                                                                                         Screening for reproductive/ developmental toxicity                                                                       
  Hazard on the environment   Acute toxicity on fish                                                     Fresh water algae growth inhibition test             Inherent biodegradability                                           Further information on the environmental fate and behavior
                              Ready biodegradability                                                                                                          Identification of degradation products                              
                              Acute daphnia immobilization test                                          Biodegradation as a function of pH                   Chronic toxicity on fish                                            Chronic toxicity on terrestrial plants
                                                                                                                                                              Chronic toxicity on preferred species daphnia                       Chronic toxicity testing on terrestrial invertebrates
                                                                                                                                                              Acute toxicity on terrestrial plants                                Further information on adsorption/ desorption depending on the results of the study
                                                                                                                                                              Activated sludge respiration inhibition Adsorption/desorption       
                                                                                                                                                                                                                                  Long-term toxicity to sediment organisms
                                                                                                                                                                                                                                  Bio-concentration

Test items for lower tonnage are also required.

###### 

Number of animals required for the assessment of human health effects

                                            Cost^[a](#tfn3-eht-31-e2016026){ref-type="table-fn"}^ per substance   Primary species   Second species   Primary species (second cohorts)
  ----------------------------------------- --------------------------------------------------------------------- ----------------- ---------------- ----------------------------------
  Acute toxicity for oral                   2948571^[a](#tfn3-eht-31-e2016026){ref-type="table-fn"}^              24                                 
  Acute toxicity for dermal or inhalation   3338333^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^              40                                 
  Skin irritation and corrosion             3186000^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^              3                                  
  Skin sensitization                        13195000^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^             45                                 
  Eye irritation and corrosion              3186000^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^              3                                  
  Repeated dose toxicity (28 d)             78637500^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^             60                60               
  Repeated dose toxicity (90 d)             90000000^[c](#tfn5-eht-31-e2016026){ref-type="table-fn"}^             120               100              
  *In vivo* mutagenicity/genotoxicity       9580517^[b](#tfn4-eht-31-e2016026){ref-type="table-fn"}^              25-80                              
  Carcinogenicity                           1000000000^[c](#tfn5-eht-31-e2016026){ref-type="table-fn"}^           500               500              
  Two generation                            270000000^[c](#tfn5-eht-31-e2016026){ref-type="table-fn"}^            200               240              
  Reproductive toxicity                                                                                                                              
  Reproductive toxicity screening           62000000 -70000000^[c](#tfn5-eht-31-e2016026){ref-type="table-fn"}^   675                                
  Total                                     1540071921                                                                                               5975

GLP, good laboratory practice; CRO, contract research organization.

Unit Korean won.

Ministry of Environment 2016 (average price of 15 GLP-CROs).

From a single GLP-CRO.

###### 

OECD TGs and number of animal reduction by an alternative test methods based on 3R

  Toxic endpoint                   OECD TG No.   Title                                                                                                                                                                                          *In vivo*/*in vitro*   3R                     Year   No. of animals used
  -------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ---------------------- ------ ---------------------
  Acute toxicity                   420           Acute oral toxicity: fixed dose procedure                                                                                                                                                      *In vivo*              Refinement             2002   20
                                   423           Acute oral toxicity: acute toxic class method                                                                                                                                                  *In vivo*              Reduction              2002   12
                                   425           Acute oral toxicity: up-and-down procedure                                                                                                                                                     *In vivo*              Refinement/reduction   2008   9
  Skin irritation and              404           Acute dermal irritation/corrosion                                                                                                                                                              *In vivo*              Refinement             2015   3-4
  corrosion                        430           *In vitro* skin corrosion: transcutaneous electrical resistance test method                                                                                                                    *In vitro*             Replacement            2015   0
                                   431           *In vitro* skin corrosion: reconstructed human epidermis test method                                                                                                                           *In vitro*             Replacement            2015   0
                                   435           *In vitro* membrane barrier test method for skin corrosion                                                                                                                                     *In vitro*             Replacement            2015   0
                                   439           *In vitro* skin irritation: reconstructed human epidermis test method                                                                                                                          *In vitro*             Replacement            2015   0
  Skin sensitization               429           Skin sensitization: local lymph node assay                                                                                                                                                     *In vivo*              Reduction              2010   24
                                   442A          Skin sensitization: local lymph node assay: DA                                                                                                                                                 *In vivo*              Refinement/reduction   2010   24
                                   442B          Skin sensitization: local lymph node assay: BrdU-ELISA                                                                                                                                         *In vivo*              Refinement/reduction   2010   24
                                   442C          In chemico skin sensitization: direct peptide reacitivity assay                                                                                                                                *In vitro*             Replacement            2015   0
                                   442D          *In vitro* skin sensitization: ARE-Nrf2 luciferase test method                                                                                                                                 *In vitro*             Replacement            2015   0
                                   442E          *In vitro* skin sensitisation: human cell line activation test                                                                                                                                 *In vitro*             Replacement            2016   0
  Eye irritation and               405           Acute eye irritation/corrosion                                                                                                                                                                 *In vivo*              Refinement             2012   1-3
  corrosion                        437           Bovine corneal opacity and permeability test method                                                                                                                                            *In vitro*             Replacement            2013   0
                                   438           Isolated chicken eye test method                                                                                                                                                               *In vitro*             Replacement            2013   0
                                   460           Fluorescein leakage test method for identifying ocular corrosives and severe irritants                                                                                                         *In vitro*             Replacement            2012   0
                                   491           Short time exposure *In vitro* test method for identifying; i) chemicals inducing serious eye damage and ii) chemicals not requiring classification for eye irritation or serious eye damage   *In vitro*             Replacement            2015   0
                                   492           Reconstructed human cornea-like epithelium test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage                           *In vitro*             Replacement            2015   0
  Dermal/percutaneous absorption   428           Skin absorption: *in vitro* method                                                                                                                                                             *In vitro*             Replacement            2004   0
  Mutagenicity/                    471           Bacterial reverse mutation test                                                                                                                                                                *In vitro*             Replacement            1997   0
  genotoxicity                     473           *In vitro* mammalian chromosomal aberration test                                                                                                                                               *In vitro*             Replacement            2014   0
                                   474           Mammalian erythrocyte micronucleus test                                                                                                                                                        *In vivo*              Refinement             2014   23-35
                                   475           Mammalian bone marrow chromosomal aberration test                                                                                                                                              *In vivo*              Refinement             2014   45
                                   476           *In vitro* mammalian cell gene mutation tests using the hprt and xprt genes                                                                                                                    *In vitro*             Replacement            2015   0
                                   478           Rodent dominant lethal test                                                                                                                                                                    *In vivo*              Refinement             2015   96-120
                                   483           Mammalian spermatogonial chromosomal aberration test                                                                                                                                           *In vivo*              Refinement/reduction   2015   45
                                   487           *In vitro* mammalian cell micronucleus test                                                                                                                                                    *In vitro*             Replacement            2014   0
                                   488           Transgenic rodent somatic and germ cell gene mutation assays                                                                                                                                   *In vivo*              Refinement             2013   25
                                   489           *In vivo*mammalian alkaline comet assay                                                                                                                                                        *In vivo*              Refinement/reduction   2014   25\~35
                                   490           *In vitro* mammalian cell gene mutation tests using the thymidine kinase gene                                                                                                                  *In vitro*             Replacement            2015   0
  Reproductive toxicity            421           Reproduction/developmental toxicity screening test                                                                                                                                             *In vivo*              Refinement/reduction   2015   90
                                   422           Combined repeated dose toxicity study with the reproduction/ developmental toxicity screening test                                                                                             *In vivo*              Refinement/reduction   2015   90
                                   443           Extended one- generation reproductive toxicity study                                                                                                                                           *In vivo*              Refinement/reduction   2012   140
  Photo-induced toxicity           432           *In vitro* 3T3 NRU phototoxicity test                                                                                                                                                          *In vitro*             Replacement            2004   0
  Carcinogenicity                  453           Combined chronic toxicity/carcinogenicity studies                                                                                                                                              *In vivo*              Reduction              2009   560

OECD, Organization for Economic Cooperation and Development; TG, test guidelines; 3R, replacement, reduction or refinement; BrdU-ELISA, bromodeoxyuridine-enzyme-linked immunosorbent assay; ARE-Nrf2, antioxidant responsive element binded NF-E2-related factor 2; DA, developed by Daicel Chemical Industries, Ltd; NRU, neutral red uptake.

###### 

Category and tools employed for OECD TGs based on non-animal based methodology

  Category       OECD TG No.   Toxi endpoints                   Title                                                                                                                                                                                         System and tools employed
  -------------- ------------- -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  *Ex vivo*      437           Eye irritation/corrosion         Bovine corneal opacity and permeability test method                                                                                                                                           Isolated corneas from the eyes of cattle slaughtered (UV absorbance/Opacimeter)
                 438           Eye irritation/corrosion         Isolated chicken eye test method                                                                                                                                                              Eyes of slaughtered chicken (slit-lamp microscopes)
                 460           Eye irritation/corrosion         Fluorescein Leakage test method for identifying ocular corrosives and severe irritants                                                                                                        Confluent monolayer of Madin-Darby canine kidney (UV absorbance)
  *In vitro*     430           Skin corrosion                   *In vitro* skin corrosion: transcutaneous electrical resistance test method                                                                                                                   Rat skin disk (voltohmmeter)
                 431           Skin corrosion                   *In vitro* skin corrosion: reconstructed human epidermis test method                                                                                                                          Reconstructed human epidermis (3D tissue engineering)
                 435           Skin corrosion                   *In vitro* membrane barrier test method for skin corrosion                                                                                                                                    Artificial membrane
                 439           Skin irritation                  *In vitro* skin irritation: reconstructed human epidermis test method                                                                                                                         Reconstructed human epidermis (3D tissue engineering)
                 442D          Skin sensitization               *In vitro* skin sensitization: ARE-Nrf2 luciferase test method                                                                                                                                Cell line which contains the luciferase gene under the transcriptional control of a constitutive promoter fused with an are element (reporter gene assay)
                 442E          Skin sensitization               *In vitro* skin sensitisation: human cell line activation test                                                                                                                                Human monocytic leukaemia cell line THP-1
                 491           Eye irritation/corrosion         Short time exposure *in vitro* test method for identifying i) chemicals inducing serious eye damage and ii) chemicals not requiring classification for eye irritation or serious eye damage   Statens seruminstitut rabbit cornea cells
                 492           Eye irritation/corrosion         Reconstructed human cornea-like epithelium test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage                          Reconstructed human cornea-like epithelium (3D tissue engineering)
                 428           Dermal/percutaneous absorption   Skin absorption: *in vitro* method                                                                                                                                                            Viable or non-viable human (animal) skin
                 471           Mutagenicity/genotoxicity        Bacterial reverse mutation test                                                                                                                                                               Salmonella typhimurium, escherichia coli
                 473           Mutagenicity/genotoxicity        *In vitro* mammalian chromosomal aberration test                                                                                                                                              Mammalian somatic cells
                 476           Mutagenicity/genotoxicity        *In vitro* mammalian cell gene mutation tests using the HPRT and XPRT genes                                                                                                                   Mammalian cells (ex. cho, chl)
                 487           Mutagenicity/genotoxicity        *In vitro* mammalian cell micronucleus test                                                                                                                                                   Mammalian cells (ex. blood lymphocytes)
                 490           Mutagenicity/genotoxicity        *In vitro* mammalian cell gene mutation tests using the thymidine kinase gene                                                                                                                 L5178Y tk+/-3.7.2C cells for the mouse lymphoma assay, TK6 tk+/- cells for the TK6 assay
                 432           Photo-cytotoxicity               *In vitro* 3T3 NRU phototoxicity test                                                                                                                                                         Balb/c 3T3 cells
  *In chemico*   442C          Skin sensitization               *In chemico* skin sensitization: direct peptide reactivity assay                                                                                                                              Synthetic peptides (LC/UV)

OECD, Organization for Economic Cooperation and Development; TG, test guideline; UV, ultraviolet; 3D, three-dimensional; HPRT, hypoxanthine-guanine phosphoribosyl transferase; XPRT, xanthine phosphoribosyl transferase; NRU, neutral red uptake; LC, liquid chromatography.
